Pricing
  1. JP-listed companies
  2. ReproCELL Incorporated
  3. Financials
  4. Stockholders' equity

ReproCELL Incorporated【JP:4978】

Market cap
¥16B
P/E ratio
-27.8x
Reprocell develops iPS cell technology for research and medical applications, providing lab products and services to pharmaceutical companies while advancing regenerative medicine treatments.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndStockholders' equity (Million JPY)YoY (%)
Mar 31, 20258,985+8.10%
Mar 31, 20248,312+9.72%
Mar 31, 20237,575+4.47%
Mar 31, 20227,251+34.50%
Mar 31, 20215,391-11.01%
Mar 31, 20206,058-14.33%
Mar 31, 20197,071+13.17%
Mar 31, 20186,248-15.20%
Mar 31, 20177,369+1.39%
Mar 31, 20167,268+2.58%
Mar 31, 20157,085+36.38%
Mar 31, 20145,195

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)